Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Phase I study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts.

Bang YJ, Su WC, Schuler M, Nam DH, Lim WT, Bauer TM, Azaro A, Poon RTP, Hong D, Lin CC, Akimov M, Ghebremariam S, Zhao S, Giovannini M, Ma B.

Cancer Sci. 2019 Nov 28. doi: 10.1111/cas.14254. [Epub ahead of print]

2.

Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.

Piha-Paul SA, Taylor MH, Spitz D, Schwartzberg L, Beck JT, Bauer TM, Meric-Bernstam F, Purkayastha D, Karpiak L, Szpakowski S, Braiteh F.

Oncotarget. 2019 Nov 5;10(60):6526-6535. doi: 10.18632/oncotarget.27251. eCollection 2019 Nov 5.

3.

Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors.

Jung SY, Yug JS, Clarke JM, Bauer TM, Keedy VL, Hwang S, Kim SJ, Chung EK, Lee JI.

Cancer Chemother Pharmacol. 2019 Oct 30. doi: 10.1007/s00280-019-03979-z. [Epub ahead of print]

PMID:
31673825
4.

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.

Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI.

Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25.

PMID:
31669155
5.

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.

Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM.

Lancet Oncol. 2019 Nov;20(11):1544-1555. doi: 10.1016/S1470-2045(19)30514-5. Epub 2019 Sep 25. Erratum in: Lancet Oncol. 2019 Dec;20(12):e663.

PMID:
31563517
6.

Perfused murine heart optical transmission spectroscopy using optical catheter and integrating sphere: Effects of ischemia/reperfusion.

Bauer TM, Giles AV, Sun J, Femnou A, Covian R, Murphy E, Balaban RS.

Anal Biochem. 2019 Dec 1;586:113443. doi: 10.1016/j.ab.2019.113443. Epub 2019 Sep 17.

PMID:
31539522
7.

A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.

Abramson VG, Oliveira M, Cervantes A, Wildiers H, Patel MR, Bauer TM, Bedard PL, Becerra C, Richey S, Wei MC, Reyner E, Bond J, Cui N, Wilson TR, Moore HM, Saura C, Krop IE.

Breast Cancer Res Treat. 2019 Nov;178(1):121-133. doi: 10.1007/s10549-019-05360-3. Epub 2019 Jul 31.

PMID:
31368034
8.

Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.

Jung SY, Hwang S, Clarke JM, Bauer TM, Keedy VL, Lee H, Park N, Kim SJ, Lee JI.

Invest New Drugs. 2019 Jul 13. doi: 10.1007/s10637-019-00835-y. [Epub ahead of print]

PMID:
31300967
9.

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC.

Bauer TM, Besse B, Martinez-Marti A, Trigo JM, Moreno V, Garrido P, Ferron-Brady G, Wu Y, Park J, Collingwood T, Kruger RG, Mohammad HP, Ballas MS, Dhar A, Govindan R.

J Thorac Oncol. 2019 Oct;14(10):1828-1838. doi: 10.1016/j.jtho.2019.06.021. Epub 2019 Jun 28.

10.

A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.

Harding JJ, Zhu AX, Bauer TM, Choueiri TK, Drilon A, Voss MH, Fuchs CS, Abou-Alfa GK, Wijayawardana SR, Wang XA, Moser BA, Uruñuela A, Wacheck V, Bendell JC.

Clin Cancer Res. 2019 Sep 1;25(17):5202-5211. doi: 10.1158/1078-0432.CCR-18-4010. Epub 2019 May 29.

PMID:
31142504
11.

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF.

J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20.

PMID:
30892989
12.

Clinical Management of Adverse Events Associated with Lorlatinib.

Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, Shaw AT.

Oncologist. 2019 Aug;24(8):1103-1110. doi: 10.1634/theoncologist.2018-0380. Epub 2019 Mar 19.

PMID:
30890623
13.

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2019 Mar 14;7(1):73. doi: 10.1186/s40425-019-0559-3.

14.

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.

Faessel H, Nemunaitis J, Bauer TM, Lockhart AC, Faller DV, Sedarati F, Zhou X, Venkatakrishnan K, Harvey RD.

Br J Clin Pharmacol. 2019 Jul;85(7):1464-1473. doi: 10.1111/bcp.13915. Epub 2019 May 17.

15.

Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedure.

Bauer TM, Dhir T, Strickland A, Thomsett H, Goetz AB, Cannaday S, Brody JR, Pishvaian MJ, Yeo CJ.

J Pancreat Cancer. 2018 Nov 1;4(1):81-87. doi: 10.1089/pancan.2018.0015. eCollection 2018. Review.

16.

The Legend of George J. Willauer, M.D. (1896-1977).

Dworkin MS, Salmons H, Bauer TM, Tchantchaleishvili V, Yeo CJ, Cowan SW.

Am Surg. 2018 Nov 1;84(11):e487-e489. No abstract available.

PMID:
30747661
17.

Bernard J. Miller, M.D., Sc.D. (Hon.) (1918-2007): The Life and Scientific Contributions of a Crucial Figure in the Development of the Heart-Lung Machine.

Bauer TM, Dworkin MS, Miller SB, Yeo CJ, Cowan SW.

Am Surg. 2018 Nov 1;84(11):e472-e474. No abstract available.

PMID:
30747656
18.

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.

Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, Taylor M, Shaw AT, Montez S, Meric-Bernstam F, Smith S, Tuch BB, Ebata K, Cruickshank S, Cox MC, Burris HA, Doebele RC.

Ann Oncol. 2019 Feb 1;30(2):325-331. doi: 10.1093/annonc/mdy539.

19.

3D organ modeling with open-source software.

Cross DE, Bauer TM, Tchantchaleishvili V.

Artif Organs. 2019 Jun;43(6):596-598. doi: 10.1111/aor.13395. Epub 2018 Dec 25.

PMID:
30468517
20.

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.

Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, Gilbert L, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK.

Clin Cancer Res. 2019 Mar 15;25(6):1727-1736. doi: 10.1158/1078-0432.CCR-18-2474. Epub 2018 Nov 9.

PMID:
30413525
21.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT.

Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30413378
22.

Highlights From the 64th Annual Meeting of the American Society for Artificial Internal Organs.

Bauer TM, Phillips SJ, Tchantchaleishvili V.

Artif Organs. 2018 Oct;42(10):E325-E334. doi: 10.1111/aor.13356. No abstract available.

PMID:
30375676
23.

Adherence to Inpatient Venous Thromboembolism Prophylaxis: A Single Institution's Concurrent Review.

Bauer TM, Johnson AP, Dukleska K, Beck J, Dworkin MS, Patel K, Cowan SW, Merli GJ.

Am J Med Qual. 2019 Jul/Aug;34(4):402-408. doi: 10.1177/1062860618808378. Epub 2018 Oct 26.

PMID:
30360638
24.

Device exchange versus nonexchange modalities in left ventricular assist device-specific infections: A systematic review and meta-analysis.

Bauer TM, Choi JH, Luc JGY, Weber MP, Moncho Escrivá E, Patel S, Maynes EJ, Boyle AJ, Samuels LE, Entwistle JW, Morris RJ, Massey HT, Tchantchaleishvili V.

Artif Organs. 2019 May;43(5):448-457. doi: 10.1111/aor.13378. Epub 2018 Nov 25.

PMID:
30357880
25.

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2018 Oct 22;6(1):109. doi: 10.1186/s40425-018-0420-0. Erratum in: J Immunother Cancer. 2019 Mar 14;7(1):73.

26.

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K.

J Clin Oncol. 2018 Nov 20;36(33):3298-3306. doi: 10.1200/JCO.2018.78.7697. Epub 2018 Oct 4. Erratum in: J Clin Oncol. 2019 Jan 20;37(3):261.

PMID:
30285518
27.

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).

Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao Y, Gong X, Maleski J, Leopold L, Gajewski TF.

J Clin Oncol. 2018 Sep 28:JCO2018789602. doi: 10.1200/JCO.2018.78.9602. [Epub ahead of print]

28.

The Person Behind the Inventor of the Heart-Lung Machine: John H. Gibbon Jr, MD (1903-1973).

Bauer TM, Tchantchaleishvili V.

Artif Organs. 2018 Aug;42(8):765-775. doi: 10.1111/aor.13280. No abstract available.

PMID:
30178889
29.

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.

Harding JJ, Bauer TM, Tan DSW, Bedard PL, Rodon J, Doi T, Schnell C, Iyer V, Baffert F, Radhakrishnan R, Fabre C, Juric D.

Invest New Drugs. 2019 Apr;37(2):271-281. doi: 10.1007/s10637-018-0627-4. Epub 2018 Aug 3.

30.

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.

Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A.

Invest New Drugs. 2019 Feb;37(1):87-97. doi: 10.1007/s10637-018-0610-0. Epub 2018 May 21.

31.

Signature program: a platform of basket trials.

Slosberg ED, Kang BP, Peguero J, Taylor M, Bauer TM, Berry DA, Braiteh F, Spira A, Meric-Bernstam F, Stein S, Piha-Paul SA, Salvado A.

Oncotarget. 2018 Apr 20;9(30):21383-21395. doi: 10.18632/oncotarget.25109. eCollection 2018 Apr 20.

32.

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors.

Bauer TM, Patel MR, Forero-Torres A, George TJ Jr, Assad A, Du Y, Hurwitz H.

Onco Targets Ther. 2018 Apr 30;11:2399-2407. doi: 10.2147/OTT.S157331. eCollection 2018.

33.

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.

Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe E, Fink A, Wacheck V, Moore KN.

Clin Cancer Res. 2018 Jul 15;24(14):3253-3262. doi: 10.1158/1078-0432.CCR-17-3421. Epub 2018 Apr 10.

34.

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.

Moore KN, Bauer TM, Falchook GS, Chowdhury S, Patel C, Neuwirth R, Enke A, Zohren F, Patel MR.

ESMO Open. 2018 Feb 1;3(2):e000291. doi: 10.1136/esmoopen-2017-000291. eCollection 2018.

35.

Is nonoperative management of partial distal biceps tears really successful?

Bauer TM, Wong JC, Lazarus MD.

J Shoulder Elbow Surg. 2018 Apr;27(4):720-725. doi: 10.1016/j.jse.2017.12.010. Epub 2018 Feb 1.

PMID:
29396100
36.

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ.

Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23.

37.

Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study.

Brown J, Plummer R, Bauer TM, Anthony S, Sarantopoulos J, De Vos F, White M, Schupp M, Ou Y, Vaishampayan U.

Exp Hematol Oncol. 2017 Oct 3;6:27. doi: 10.1186/s40164-017-0086-1. eCollection 2017.

38.

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.

Zhou X, Pant S, Nemunaitis J, Craig Lockhart A, Falchook G, Bauer TM, Patel M, Sarantopoulos J, Bargfrede M, Muehler A, Rangachari L, Zhang B, Venkatakrishnan K.

Invest New Drugs. 2018 Apr;36(2):248-258. doi: 10.1007/s10637-017-0499-z. Epub 2017 Aug 30.

39.

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies.

Zhou X, Nemunaitis J, Pant S, Bauer TM, Patel M, Sarantopoulos J, Craig Lockhart A, Goodman D, Huebner D, Mould DR, Venkatakrishnan K.

Invest New Drugs. 2018 Apr;36(2):240-247. doi: 10.1007/s10637-017-0498-0. Epub 2017 Aug 18.

40.

Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.

Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ.

Cancer. 2017 Aug 15;123(16):3080-3087. doi: 10.1002/cncr.30736. Epub 2017 Apr 25.

41.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG.

Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.

42.

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.

Bang YJ, Giaccone G, Im SA, Oh DY, Bauer TM, Nordstrom JL, Li H, Chichili GR, Moore PA, Hong S, Stewart SJ, Baughman JE, Lechleider RJ, Burris HA.

Ann Oncol. 2017 Apr 1;28(4):855-861. doi: 10.1093/annonc/mdx002.

43.

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ.

J Clin Oncol. 2017 Apr 1;35(10):1112-1118. doi: 10.1200/JCO.2016.69.9538. Epub 2016 Dec 28.

44.

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators.

Lancet Oncol. 2017 Jan;18(1):42-51. doi: 10.1016/S1470-2045(16)30565-4. Epub 2016 Dec 5.

45.

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.

Infante JR, Hollebecque A, Postel-Vinay S, Bauer TM, Blackwood EM, Evangelista M, Mahrus S, Peale FV, Lu X, Sahasranaman S, Zhu R, Chen Y, Ding X, Murray ER, Schutzman JL, Lauchle JO, Soria JC, LoRusso PM.

Clin Cancer Res. 2017 May 15;23(10):2423-2432. doi: 10.1158/1078-0432.CCR-16-1782. Epub 2016 Nov 4.

46.

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR.

J Clin Oncol. 2016 Oct 10;34(29):3562-3569. doi: 10.1200/JCO.2016.68.1106.

47.

A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors.

Bendell JC, Bauer TM, Lamar R, Joseph M, Penley W, Thompson DS, Spigel DR, Owera R, Lane CM, Earwood C, Burris HA 3rd.

Cancer Invest. 2016 Jul 2;34(6):265-70. doi: 10.1080/07357907.2016.1193746. Epub 2016 Jul 5.

PMID:
27379708
48.

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J.

J Clin Oncol. 2016 May 20;34(15):1764-71. doi: 10.1200/JCO.2015.64.5788. Epub 2016 Apr 4. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):356.

49.

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.

Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT.

J Thorac Oncol. 2015 Dec;10(12):1670-4. doi: 10.1097/01.JTO.0000473485.38553.f0.

50.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA.

Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13.

Supplemental Content

Loading ...
Support Center